Health In Tech (HIT) grants 200K restricted shares to Chief Growth Officer

Rhea-AI Filing Summary

Health In Tech, Inc. reported that Chief Growth Officer Hasan Zain Syed received 200,000 restricted shares of Class A common stock on January 6, 2026 under the Health in Tech Equity Incentive Plan. These shares are tied to two proposed issuer transactions. Half of the grant vests in equal monthly installments over 12 months starting at the closing of the first transaction, and the other half vests monthly over 12 months starting at the closing of the second transaction, in each case subject to continued service. If either transaction does not close within 24 months after January 6, 2026, the unvested shares relating to that transaction will be automatically forfeited without payment. Following this grant, Syed beneficially owns 220,000 restricted shares of Class A common stock, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hasan Zain Syed

Role Chief Growth Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	200,000	$0.00	--

Holdings After Transaction: Class A Common Stock — 220,000 shares (Direct)

Footnotes (1)

1. Represents restricted shares of Class A Common Stock granted pursuant to the Health in Tech Equity Incentive Plan in connection with two proposed issuer transactions (each, a "Transaction"). Half of the shares vest in equal monthly installments over 12 months starting at the closing of the first Transaction ("First Transaction Shares"). The other half vest in equal monthly installments over 12 months starting at the closing of the second Transaction ("Second Transaction Shares"). Vesting is subject to continued service. If either Transaction does not close within 24 months after January 6, 2026 (the "Grant Date"), unvested shares relating to that Transaction will be automatically forfeited without consideration. Includes 220,000 shares of restricted shares of Class A Common Stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hasan Zain Syed

(Last) (First) (Middle)

701 S. COLORADO AVE,

SUITE 1

(Street)

STUART FL 34994

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Health In Tech, Inc. [ HIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Growth Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/06/2026		A		200,000(1)	A	$0	220,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted shares of Class A Common Stock granted pursuant to the Health in Tech Equity Incentive Plan in connection with two proposed issuer transactions (each, a "Transaction"). Half of the shares vest in equal monthly installments over 12 months starting at the closing of the first Transaction ("First Transaction Shares"). The other half vest in equal monthly installments over 12 months starting at the closing of the second Transaction ("Second Transaction Shares"). Vesting is subject to continued service. If either Transaction does not close within 24 months after January 6, 2026 (the "Grant Date"), unvested shares relating to that Transaction will be automatically forfeited without consideration.

2. Includes 220,000 shares of restricted shares of Class A Common Stock.

	/s/ Zain Hasan	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Health In Tech (HIT) disclose in this Form 4?

The company disclosed that Chief Growth Officer Hasan Zain Syed was granted 200,000 restricted shares of Class A common stock on January 6, 2026 under the Health in Tech Equity Incentive Plan.

How do the 200,000 restricted shares granted to Hasan Zain Syed vest at Health In Tech (HIT)?

Half of the restricted shares vest in equal monthly installments over 12 months starting at the closing of the first proposed transaction, and the other half vest monthly over 12 months starting at the closing of the second proposed transaction, subject to continued service.

What happens to the restricted shares if the proposed transactions at Health In Tech (HIT) do not close?

If either proposed transaction does not close within 24 months after January 6, 2026, any unvested restricted shares relating to that specific transaction will be automatically forfeited without consideration.

How many Health In Tech (HIT) shares does Hasan Zain Syed own after this grant?

After the reported grant, Hasan Zain Syed beneficially owns 220,000 restricted shares of Health In Tech Class A common stock, held directly.

Was there any cash paid for the restricted shares granted to the Health In Tech (HIT) executive?

The reported transaction shows an acquisition of 200,000 restricted shares of Class A common stock at a stated price of $0 per share.

Which executive at Health In Tech (HIT) received this equity grant and what is their role?

The equity grant was made to Hasan Zain Syed, who serves as the company's Chief Growth Officer.